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Patients with New York Heart Association functional class 11 or
III heart failure stabilized on furosemide therapy were entered
into a randomized controlled trial comparing enalapril (n = 72)
and digoxin (n = 73). End points were clinical outcome, treadmill
exercise capacity and eehocardiographic left ventricular dimen-
sions . Improvement in clinical outcome was defined as a reduction
of at least one functional class, and deterioration as an increase of
at least one functional class or withdrawal because of an adverse
clinical event .
After 4 weeks, 13 patients receiving enalapril showed improve-
ment, 55 had no change and 9 manifested deterioration compared
with 7, 49 and 17, respectively, in the digoxin group (p < 0 .01) .
After 14 weeks, 13 patients receiving enalapril showed improve .
Angiotensin-convening enzyme inhibitors are effective ther-
apy for patients with severe congestive heart failure and
have been shown to both alleviate symptoms (1-5) and
improve prognosis (6,7) . Recent evidence (8) also shows that
treatment with digoxin results in improvement in functional
capacity and exercise time . Beaune (9) compared the effi-
cacy of enalapril and digoxin in patients with hear[ failure
and found no significant difference between the two agents
.
However, the inclusion of patients in functional classes l and
IV and patients with atrial fibrillation complicates the inter-
pretation of these results, as does the fact that ventricular
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ment, 50 had no change and 9 manifested deterioration, compared
with 14, 37 and 22, respectively, In the digoxin group (p < 0 .025).
More patients in the digoxin group were withdrawn because of an
adverse clinical event (p < 0 .05).
Exercise time and percent fractional shortening improved in
both groups (p < 0,001 and <0,OS, respectively), with no signif.
icant difference between groups (p > 0 .50). Both rule-pressure
product and subjectively evaluated exertion during submaximal
exercise were reduced enty in the enalapril group
. Although the
majority of patients in both groups did well, those receiving
enalapril experienced fewer adverse clinical events and had less
fatigue during submaximal exercise.
(J Am Call Cardiol 1991:18
:1602-9)
function was not measured
. The Captopril-Digoxin Multi-
center Study (I) compared captopril, digoxin and placebo in
patients with class 11 or III hear) failure and showed a
statistically significant clinical improvement with captopril
but not digoxin . However, the degree of improvement in the
digoxin group approached statistical significance and the
study was unable to show a significant difference between
the two drugs. Also, patients whose clinical status deterio-
rated during a baseline washout phase had to be excluded
because of the possibility of randomization to placebo . This
exclusion of digoxin responders potentially biases the study
design against digoxin . The relative efficacy of angiotensin-
converting enzyme i,,hibilors and digoxin in patients with
heart failure receiving diuretic drugs therefore remains un-
certain .
Our objective was to compare angiotensin-converting
enzyme inhibitor therapy and digoxin in patients with func-
tional class II or III heart failure, documented left ventricu-
lar dysfunction and normal sinus rhythm
. We conducted a
randomized, double-blind, parallel study in which patients
initially stabilized on furoscmide therapy were then random-
ized to receive either enalapril or digoxin . To minimize
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potential bias against digoxin . a placebo study arm was not
included,
Methods
The study was conducted in the 17 Canadian centers
listed in the Appendix and performed it compliance with the
Medical Research Council of Canada (
uidelines con
.erning
the protection of the rights and
welfare
of human subjects .
The study received Ethics Committee Approval at al . par-
ticipating centers and all subjects pro% ided written informed
consent.
Eligibility . Clinically stable patien s of either gender be-
tween the ages of 18 and 75 years with New York Heart
Association functional class II or III symptoms of heart
failure and evidence of left ventricular dysfunction docu-
mented within the previous 6 motths were eligible for
inclusion in the study . Criteria for b ft ventricular dysfunc-
tion were II end-diastolic diameter >6 cm or percent frac-
tional shortening <25% on eehocerciography . or 2) ejection
fraction <50% on contrast or radio tuclide angiography. In
addition, eligible patients had docuriented physical signs or
chest X-ray evidence of left heart d tsfunction at some time
in the past. The former included pulmonary roles or a third
heart sound . The latter included act rdiothoracic ratio >0 .50
or a transverse diameter of the heat exceeding the normal
value for the patient's weight and III ight by > 10% and signs
of pulmonary venous hypertension .
Exclusion criteria included anyiotensin-convert!n en-
zyme inhibitor use within the previous month : unstable
angina, myocardial infarction or c-.urebrovascular accident
within 3 months; hypertension (>16005 mm Hgl or clinically
important renal, hepatic or hematologic disorders ; hemody-
namically significant primary valvular or congenital heart
disease : hypertrophic cardiomyopaihy : atrial arrhythmias :
predominant right-sided heart failure : the use of medications
known to interact with digoxin (such as quinidine or amio-
darone); concurrent use of cardiotonic or vasodilator drugs :
a history of digoxin toxicity while taking appropriate dose,
of digoxin ; contraindications to therapy with digoxin . furo-
semide or converting enzyme inhib tars: serum creatinine
> 1 .5
mg/dl
(130 mmol/liter) or blood t rea nitrogen >25 mgldl
(8
.3 mmollliter); and any condition t they than heart failure
that could limit treadmill exercise tolerance (such as claudi-
cation, arthritis or orthopedic problems) .
Study design. The study was a louhle-blind . parallel,
multicenter clinical trial in which 145 patients whose condi-
tion had stabilized on treatment with furosemide plus pla-
cebo were then randomized to receive enalapril In = 72) or
digoxin in = 73) for a treatment period of 14 weeks . The
study consisted of a screening assessment period . a single-
blind digoxin washout phase, a baseline assessment and
randomization and clinical assessments tiler 4 and 14 weeks
of therapy
. After dose titration, patients received fixed doses
of the study drugs unless a charge was :ainically indicated .
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All s ibiects in each group also received placebo for the
alternative active medication .
Screening assessment . Study candidates underwent a
screening assessment that included a medical history . phys-
ical ezaminatinn and exercise treadmill testing using the
modified Naughton protocol 110). To qualify, patients had to
he capable of >_6 but <18 min of treadmill exercise, with
exercise tolerance limited by symptoms of heart failure such
as fatigue or dvspnea . .All patients were confirmed to be on
a sodium-restricted (>2 g total daily intake) diet and were
ma :attend o ',de same diet
throughout
the study.
Washout of digoxin, Qualifying patients were withdrawn
from active digoxin therapy and given an equivalent dose of
digoxin placebo . Patients remained on their previous dosage
of furoscmidc . Digoxin (or matching placebo) was supplied
in 0 .125-mg tablets and active furoscmidc in 20-mg tablets,
with compliance verified at each visit by pill courts . AID
vasodilators. including long-acting nitrates, were withdrawn
at that time . Patients returned after I week for a clinical
assessment and diuretic dosage adjustment, if necessary .
After a minimum of 2 weeks without digoxin therapy and
with a constant and effective dosage of furosemide . patients
returned for a baseline assessment .
Baseline assessment and randomization . The baseline as.
sessment included a phvsical examination, two-dimensional
echocardiogram and exercise treadmill test . Eligible Isr,iems
were then randomized to receive either epalapo! pit a furo-
semide plus digoxin placebo )enalapril group) or digoxin plus
furosemide plus enalapril placebo Idigoxin group',.
Titration of enalapril . Enalapril for matching placebo)
was administered at an initial dose of 5 mg twice daily
. After
the first dose . patients underwent continuous dinica) moni-
toring with hourly blood pressure measurements for a min-
imum of 4 h until the blood pressure had stabilized . The dose
was doubled every 2 weeks until one of the following
occurred : I! a 20% decrease in systolic pressure ore systolic
pressure of 90 mm Hg : 2) a >10% decrease in systolic
pressure after I min of standing: 3) symptoms of postural
hypotension: or 41 the maximal dose of 20 mg twice daily
t reached . If patients subsequently developed mild or
moderate adve-se effects possibly due to enalapril . the dose
was reduced to the next lower level .
Titration of digoxin . The initial digoxin dose was based
on body weight (<_50 kg = 0.125 mg : 51 to 79 kg = 0 .25 mg;
>N0 kg = 0.375 mg), with adjustment by the investigator
based on knowledge of patient age . renal function and other
: . Inobles hat might affect digoxin clearance
. After 2 weeks
of stable doses of digoxin or matching placebo, a trough
plasma sample was sent to a core laboratory (Ottawa Civic
Hospital) for analysis. Clinical centers were advised regard-
ing the appropriate dose adjustment when plasma levels
were eulside the therapeutic range (I to 2 nmollliter) . An
equivalent number of digoxin placebo dose adjustments
were randomly made in. the enalapril group to maintain the
double-blind protocol . If signs or symptoms consistent with
mild digoxin toxicity developed . the dose of digoxin or
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digoxin placebo was reduced without obtaining a plasma
level
. If signs or symptoms consistent with potentially seri-
ous digoxin toxicity developed . the patient was withdrawn
from the study and appropriate therapy started
.
Furosemide adjustment. Investigators adjusted the dose
of furosemide as clinically indicated
. The dose was de-
creascd if significant or symptomatic postural hypotension
occurred and was increased if signs or symptoms of wors-
ening pulmonary congestion developed
. The maximal daily
dose was 120 mg
. The dose of furosemide given during the
baseline period was maintained throughout active treatment
unless a change was clinically indicated .
Potassium supplementation
. Supplemental potassium was
withdrawn at the time of randomization
. Serum potassium
levels were measured at every visit and supplemental potas-
sium was prescribed if levels were <3 .5 mmollliter .
Clinical assessments . Clinical assessments consisted of a
medical history, physical examination and determination of
New York Heart Association functional classification . As-
sessments were made at the beginning of the singe-blind
digoxin washout period (screening), immediately before ran-
domization (baseline) and after 4 and 14 weeks of therapy .
Exercise testing. Treadmill exercise capacity was as-
sessed with use of the modified Naughton protocol at screen-
ing
. baseline and weeks 4 and 14 . Tests were scheduled at
the same time of day (3I h) and a2 h after a light meal . A
standard set of instructions was read at the beginning of each
treadmill test and a uniform amount of encouragement given
to each patient . Subjects graded the amount of perceived
exertion after each stage of the exercise protocol and at peak
exercise using the 10-point Borg scale (I I) . A patient was
randomized only if the limiting factor for exercise was
fatigue or dyspnca .
Echocardiography . Two-dimensional echocardiograms
were obtained at screening. baseline and weeks 4 and 14
.
These were done before exercise testing at the same time of
day (T I h) for individual patients . The following measure-
ments were recorded
: left ventricular internal diameter at
end-diastole, left ventricular internal diameter at end-systole
and E point to septal separation . Percent fractional shorten-
ing of the left ventricle was calculated by the following
formula:
tOO (End-diastolic diameter
- End-systolic diameter f
End-diastolic diameter .
Clinical chemistry values and hematology . Laboratory
determinations were obtained at screening, baseline and
weeks 4 and 14 . These included a complete blood count with
differential and platelet determination and measurement of
serum electrolytes, bilirubin, creative Moose, hepatic en-
zymes, total protein, albumin and uric acid . Additional
electrolyte determinations were made I week after the start
of the study medication and at 2-week intervals during
maintenance therapy .
JACC Vo1. MN u . 7
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Statistical Analysis
End points
. The planned primary end points were I) clinical
outcome and functional capacity, 2) treadmill exercise capac-
ity, and 3) change in echocardiogmphic dimensions
. Signifi-
cantly mom patients in the digoxin group were withdrawn from
the study because of clinical worsening, a factor that poten-
tially prejudices end points 2 and 3 against enalapril
. End point
I includes patients withdrawn because of clinical events and is
therefore less subject to bias
. Secondary end points were the
rest and exercise heart rate, blood pressure, rate-pressure
product (heart rate x systolic blood pressure) and the change in
rating of perceived exertion after each exercise stage . A
two-tailed alpha of =_0
.05 was considered statistically signifi-
cant .
Change in clinical outcome and functional capacity
. Clin-
icat improvement was defined as a reduction in functional
class of at least one category
. Clinical worsening was defined
as either an increase in functional class of at least one
category or the occurrence of an adverse clinical event of
sufficient severity to require withdrawal from the study .
Groups were compared by contingency table analysis with
use of the chi-square statistic with the Yates correction or
the Fisher exact test as approprtate . The primary analysis
included the 145 patients completing the study or withdraw-
ing because of an adverse clinical event. Eight patients who
withdrew for nonclinica! reasons were not included in this
analysis; this group comprised three patients who were
noncompliant with study medications, one who was with-
drawn by his family doctor for unspecified reasons and four
who withdrew because of geographic considerations
. To
guard against potential bias, we also conducted a separate
analysis including these patients .
Change in treadmill exercise time. Univariate repeated
measures analysis of variance was used to evaluate change
in exercise tolerance. Groups were compared with use of
data obtained at baseline and at weeks 4 and 14
.
Echocardiographic dimensions. Changes in echocardio-
graphic dimensions were evaluated by using paired t tests to
compare measurements obtained at weeks 4 and 14 with
baseline values.
Change in rating of perceived exertion during exercise
.
Patients rated the amount of exertion perceived subjectively
after each exercise stage using the 10-point Borg scale
(11) .
Results obtained from patients completing study weeks 4
and 14 were compared with individual baseline values by
using paired It tests . This procedure avoided any bias that
would have been caused by including baseline data from
patients subsequently withdrawn from the protocol .
Change in rest and exercise heart rate, blood pressure and
rate-pressure product . Heart rate and blood pressure were
measured at rest, after each exercise stage and at peak
exercise
. Rate-pressure product was calculated as the prod-
uct of heart rate and systolic pressure . Results obtained from
patients completing study weeks 4 and 14 were compared
with individual baseline values by using paired i tests . This
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Table I . Clinical Characteristics of 145 Randomized Patients
-a -
36and 42 in the enalepril and digoxin groups, respectively . *Previous
myxardial ttdaretion or coronary aaging= showing <700 xenosis in at least
nee pmaimel coronary,
artery . HR = hear rate: LV = let veran,alar: IN YHA
class = New York Heart Association functional class. S, = third hear sound.
avoided any bias trial would have been caused by including
baseline data from patients subsequently withdrawn from
the protocol .
Results
Patient characteristics (Table
1) . One hundred fifty-five
patients entered screening; 10 of these patients were with-
drawn, two for worsening heart failure during digoxin wash-
Table 2 . Clinical Outcome at Weeks 4 and 14 in 141 Patients
Taking Enalapril or Digoxin
(S'eek4
	
Week 14
Enalap l Digoxin 060157nl
Dlgoxm
Improvement 1311611 711011 1311811 141195%
No change 5517611 49167'7l 50 059,1
37151'ii
Worsening 41611
17(237,1 9113501 2213012 )
Total 72
73
72
71
Imp-e-1
i, b Ored n Iuwaiey of New York Heap Association
foes[nal das ning- n funt nut sluts or disc
lion because of an adverse elinicol c r L Iw'eck4 chi-- = 10 .19! p <
0 .01 : week 14 hi,R.- = 7 p < 0 075 .1
sympmmsorrur
Dth00
card.
00,19'
AA)-,
Dlhs noncyrAvo 040906'
Tidal is
25
-Endapid group hyporensien.ttohem a. Digoxingeoup : atrlalfib flan
pultosi on. hy>
.mnsen, isehemi. In = 21
. -Enalvpril stoup: anomxh and
b., of root . t. t itthemic attack_ Digoxin troop: muscle cramps tend
hyperglycemia
 ash
.hcadache and verigo. sansea a.d vomiting, pulmonary
eropiaom . C H F = congestive heart failuree
out, and 8 after randomization for reasons other than clinical
deterioration . Thus. 145 patients (109 men. 36 women) were
included in the primary analysis . The average age was 59
-
15 years and the average weight 77 ± 15 kg . The treatment
groups s oval! matched, with n significant differences
between groups in hoseline characteristics . The mean steady
state plasma digoxin level in the digoxin group was 1 .26
.
0.43 nmc.igi er . Digoxin levels were undetectable in the
enalapnl group .
Change in clinical outcome and functional capacity (Tables
2 to 4). We observed significant differences in clinical out-
come between the groups treated with enalapnl or digoxin in
favor of the es0 opril group after both 4 and 14 weeks of
therapy (Table 2)
. An "intention to treat analysis" that
included all patients withdrawn for any reason produced
similar results (week 4: chi-square = 13 .98, df = 2, p
0.001 ; week 14 : chi-square = 7 .32, df = 2, p -= 0.026) . If only
patients withdrawn for definite symptoms of heart failure are
included, the difference between groups is statistically sig-
nificant at week 4 (p < 0
.03). but not at week 14 (p = 0.08) .
Tmenmfire patients 1179,) tt'irhdresv preierelrtrely he-
cause o fan adverse clinical event .
More patients in the
digoxin 7roup withdrew by week
4 (13 of 73 vs. 4 of 72, p =
0 .037 (Fisher's exact test]) and week 14 (18 of 73 vs. 7 of 72,
p - 0 .027 [Fisher's exact test]) . Table 3 shows the reasons
for withdrawal from the study . Table 4 shows that these
Table 4. Comparison of Baseline Chumcteristics of Patients Who
Did or Did Not Withdraw From the Study Because of
Adverse
Clinical Events
Withdrawal From Study
I .VEDD and LVESD = left ventricular internal diameter al end
.dinstole
and end systole. respectively: other abbreviations as in Table 1 .
Enalapdl Dig-.
Baseline
No . 72
Age IYC 19 _ 8 59 x 9
Malelfetnale 78'W
51 ,22
Previoaly receiving digoxin tylvi of 43129
Previously receiving ruroscmide
5498 1271
(yeslnol
Prior furosemide dose Imgldayl 49 - 24 43 c
Cardiothomcrc ratio o
5,
x .n8 n
-a .
Rest HR lbemslminl
0b 0 iS e8 . I6
Exercise duration Isl 730 0'_09 665 '--04
NYHA clay 11111111 4824 4427
S, presentlabsent 147fi 37,15
Len atrium (ran,) 42 - 6 , S
LV diastolic diameter lmml 65 e 7 67 0 8
LV systolic diameter (marl 65 o 9 0 9
E point to topic! separation (ntml 21 s 10 _ 9
Radionudide ejection fraction ( 1,, 19 a 13 31
0 1'-
Scrum sodium (mmoll
141 _ 9 141 z 1,
Semen potassium (mmoh 4 .1 0 0 .4 4.1 0 0.4
semenor.adnineImneot> L2_ a .2 1.1 a.7
Etiology :ischemieflidinpaihie
52116 4625
Etioiogythype" envivel ail 19
eectire vaNNOar
Posinndominalion
Enalapril(mgldeyllrangel 19110-401
Digoxin(mgldmi verge) 0.284(11125-0,51
Furnsemidelinglday)(range) 44.7110-1601 49 .2 120-160)
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Table 3. Reason for Dimonti^.Gabon of Therapy in
Randomied Patients
1605
Enalupril ToO1
Yes ie = -'51 N. (a - 110)
p Value
#0011'11 58' II 5909 As
Exercise loleranee UI 576
0
193
725 s 202 <0.001
74)0.9 Iata It III
11114 83,37 <0.0'
S,presentubsem
1095 60160 NS
LVEDDImnll 66--8 6708 NS
LVESDImm1
55--8 5609
NS
Rest HIM (Stair mm) 93 16
e5 0 14 <O.025
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1000 rr'
900
0
baseline k week 14
Figure 1
. Maximal treadmill esercisc capacity (time) . Both treat-
ment groups showed significant improvement, with no significant
difference between the digoxin (while bars) and enalapril (black bars)
groups . Comparison is biased because or the many patients who
withdrew from the digoxin group . Error bars represent standard
deviation .
patients tended to be in functional class Ill rather than class
11, with poorer baseline exercise tolerance and higher heart
rate at rest .
Change in maximal exercise capacity, Figure I shows
maximal treadmill exercise capacity for the digoxin and
enalapril groups at baseline and weeks 4 and 14 . Both the
enalapril and digoxin groups showed significant improve-
ment (p < 0.001), with no difference between groups (p =
OA97) .
Echocardiographic dimensions (Table 5)
. Both groups
showed significant decreases in internal left ventricular
systolic dimension at week 14 and a resulting increase in
percent fractional shortening . There was no significant
change in other atrial and ventricular dimensions and no
significant differences between groups .
Change in rating of perceived exertion during exercise .
Figure 2 shows the change in rating of perceived exertion
from baseline after each exercise stage at weeks 4 and 14 .
There were significant reductions in the enalapril group, with
no significant change observed in the digoxin group,
2
t
7
c 0
m
u -1
_2
2
t
G 0
B
_2
Table 5
. Echacardiographic Measurements in the Enalapril and Digosin Groups
Worsened
Armul
Improved
1 . 2 3 . 4 . 5. 6. 7. 8.
Exercise stage
xerseaea
FF'rpprr
-
Improved
t. 2.
S. 4. 5. d . 7. B
Exercise stage
Figure 2. Change in rating of perceived exertion during exercise at
week 4 (top) and week 14 (bottom)
. White bars indicate the digoxin
group and black bars the enalapril group . ap < 0 .05 ; tp < 0.01 .
Change in rest and exercise heart rate, blood pressure and
rate-pressure product (Fig. 3). The results were similar for
patients completing week 4 and week 14
. The enalapril group
showed the expected decrease in systolic and diastolic blood
pressure at rest, with no change in heart rate at rest . The
1ACC Vol . 18. No. 7
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~p < 0
.01 ; 'p < 0.05. Valuesare mean values a SD lie parentheses)
. EPSS= E point to serial sepaalion ; other
abbreviations a.s in Table 4.
Enalapnl
Diane in
Baseline Week 4 Week 14 Baseline Week 4 Week 14
Left atrium (mm) 42(6) 41 )71 41171
43M 43 (7) 42(7)
LVEDD (mm) 66 )7) (6 )81 li6I8) 67)8)
66(8) 66)101
LVESD (mm)
55 )9) 55191 53(101'
57)111) 55 (m) 54(12)5
9,' (motional sheering
15 )10) 11171 2a (10)' 13 )5) 11 (9) 20171'
EPSS(ow) 22(10)
21191 21 (9) 23 (9) 23 )7) 23 (8)
14CC Val . 19. No. 7
Docinher 19911607-9
Figure 3 . Change in rest and eacrcim values at week 14 fur heart
rate (top), systolic blood prosure legated and rate-pre ro product
lheart rate x systolic blood pressure) . Whit, burn indicate the
digoxin group and black liars the enalapril group . -p < 0,0
: -p
0 .0) .
E
E
U
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Discussion
Enalapril versus digoxin
. In the present study, among
patients with heart failure whose condition had stabilized on
diuretic drug therapy. those receiving additional therapy
with an angietensin-converting enzyme inhibitor had a better
shor-tort.. clinical outcome and experienced less fatigue
during submaximal exercise than did those receiving dig-
oxin . However. :here was no difference in the degree of
improvement in either treadmill exercise capacity or left
ventricular function between the groups receiving enalapril
and digoxin . After 4 weeks of treatment, more patients
receiving enaapril had improved functional class . whereas
t,fter 14 weeks, the enalapril and digoxin groups were
0 Digoxin equivalent in this regard More patients in the digoxin group
∎ Eualapra
showed deterioration at both 4 and 14 weeks of therapy,
primarily because of a high withdrawal rate before the week
4 evaluation . It is unlikely that this difference was due to
chance because the treatment groups were well matched
with regain to baseline characteristics and the results were
essentially unch-mged in an intention to treat analysis that
included patients withdrawn far ncncliaical reasons .
The treaune:a effects after l4 weeks of therapy were
modest . with 18% to 199c of patients in each group showicg
clinical improvement
. The difference between the two
groups at that time was due to the greater number of patients
in the digoxin group wito withdrew from the study before 4
weeks . One possible explanation for these findings may be
that the beneficial effects of digoxin are delayed compared
with those of enalapril . Such a delay would explain why
o nigoxin more patients in the enalapril group showed improvement at
week 4 but lot at week 14, as well as way early withdrawal
was more frequent in the digoxin group . Patients withdrawn
because of clinical worsening were more likely to be in
functional class III and had poorer baseline exercise toler-
ance . This observation is consistent with the improved
∎ Enalapril
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dlgosm erase showed a slight in r systolic blood
pressure and a significant decrease in heap role . The reduc-
tion in rat -pressure product was significant in both gc .ups
but greater in the enalapril group.
The enalapril group showed a significant reduction in
systolic and diastolic blood pressure after each exercise
stage and at peak exercise
. In the digoxin group systolic
blood pressure increased but there was no change in dia-
stolic pressure Heart rate decreased in both groups at
intermediate e .xeicisc stages hilt the magnitude of the de-
crease was greater in the digoxin group . The enalapril group
showed a significant reduction in rate-pressure product at
intermediate exercise stages and peak exercise ; a smatter
reduction in the digoxin group did not reach statistical
significance.
Safety. There were no deaths during the Study . .Azotemia
developed in two patients (one in each vioupl. Otherwise.
there were no clinically Significant change, is routine hema-
tologic or dread chemistry nreasnres .
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functional capacity seen in the patients in class IV receiving
enalapril in the CONSENSUS Trial (6).
Previous studies, Two previous large studies (1,9) did not
show significant differences between angiotensin-converting
enzyme inhibitors and digoxin in the treatment of patients
with heart failure . However, both studies had important
limitations. Beaune (9) conducted a randomized double-
blind comparison of enalapril and digoxin in heart failure and
reported no difference between the two agents . These results
are difficult to interpret because that study did not measuic
left ventricular function and included patients with atrial
fibrillation as well as patients with class I and IV hart
failure . The other study (1), a randomized, double-blind,
placebo-controlled comparison of captopril and digoxin .
found a significant difference between placebo and captopril
but not between placebo and digoxin . However, the patients
randomized to digoxin showed improvement of a magnitude
that was similar to that of patients receiving captopril and
closely approached statistical significance
. There was no
statistically significant difference between the active treat-
ment groups
. In that study a significant number of patients
showed clinical deterioration during washout of digoxin and
were withdrawn from the study before randomization, thus
creating a potential bias in favor of captopril by the selective
exclusion of digoxin responders . In the present study, only
two patients were excluded before randomization because of
worsening heart failure, a number unlikely to effect the
overall result. One possible reason for the lower dropout rate
in our study is the absence of a placebo group. Because there
was no possibility of being randomized to inactive therapy,
those patients showing mild deterioration whose condition
stabilized with diuretic therapy did not have to be withdrawn
during the baseline phase .
Exercise tolerance. The major limitation of a comparison
of two active agents without a placebo group is that it does
not allow an independent assessment of the efficacy of the
individual agents
. Other studies have shown the efficacy of
enalapril (12,13) and digoxin (8 .14) individually. We found
no significant difference between the enalapril and digoxin
groups in the amount of improvement in maximal treadmill
exercise capacity. Although this capacity improved in both
groups, this result is difficult to interpret in the absence of a
placebo group. The comparison of maximal exercise capac-
ity between the two groups may have been biased against
enalapril because of the withdrawal of patients with severe
heart failure from the digoxin group
. The digoxin group
would likely have shown less improvement had these pa-
tients remained in the study .
The enalapril group showed a significant reduction in the
patients' subjective rating of perceived exertion, but the
digoxin group did not . This outcome occurred even though
the selective withdrawal of patients with more severe heart
failure from the digoxin group would also tend to bias this
comparison in favor of the digoxin group . Because the
cardiac work loads at intermediate exercise stages are more
similar to those occurring during usual daily activ
:ties, the
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rating of perceived exertion at lower levels of exercise may
have more clinical relevance than does maximal exercise
capacity.
Echocardiographic dimensions. Percent fractional short-
ening improved in both the enalapril and digoxin groups . The
decrease in systolic blood pressure in the enalapril group
suggests that improved ventricular function is a consequence
of decreased cardiac afterload, whereas the increase in this
variable in the digoxin group is consistent with 'he positive
inotropic effect of this agent .
Effects on heal rate, blood pressure and cardiac work
load . As anticipated, enalapril reduced both systolic and
diastolic blood pressure at rest, after each intermediate
exercise stage and at peak exercise . There was also a small
reduction in exercise heart rate, The net effect was to reduce
the rate-pressure product both at rest and with exercise . In
contrast, digoxin caused a significant decrease in rest and
exercise heart rate and a significant increase in rest and
exercise systolic blood pressure . The net effect was no
significant change in rate-pressure product during exercise
and a small but significant reduction at rest . The reduced
work loads at intermediate exercise stages in the enalapril
group were associated with a reduction in the rating of
perceived exertion . Further research will determine if there
is a cause and effect relation .
The ef fect of enalapril on cardiac work load at rest and
during exercise is consistent with its generally recognized
mechanism of action, that of an aflerload-reducing agent . It
is likely that the reduction in myocardial work load has a
long-term beneficial effect on myocardial function. Digoxin
also caused a reduction in myocardial work load at rest as a
result of its depressant effect on heart rate . Recent data
showing a relative inefficacy of more potent positive inotro-
pie agents (8,15-18) suggest that positive inotropism by itself
may not be sufficient to produce long-term benefits
. The
negative chronotropic effect of digoxin, by reducing cardiac
work load, may be at least partially responsible for its
long-term efficacy .
Clinical s ignificance. it
is now well appreciated that it is
extremely difficult to assess the effects of drugs for the
treatment of congestive heart failure because of the difficulty
in selecting end points that are clinically meaningful, other
than their effects on long-term mortality . In the present
study, after stabilization on diuretic therapy, the majority of
patients receiving either enalapril or digoxin had a similar
degree of improvement in maximal treadmill exercise capac-
ity and left ventricular function and no change in functional
class . However, those patients receiving enalapril experi-
enced a better short-term clinical outcome and more subjec-
tive improvement in treadmill exercise tolerance at submax-
imal work loads . The relation between these end points and
long-term prognosis is not known . However, a reduction in
perceived exertion at work loads representative of those
occurring during usual activities may improve the quality of
life and functional capacity . Compared with enalapril, dig-
oxin has a more marked negative chronotropic effect and
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increases rather than decreases systolic bland pressure . the
complementary hemodynamlc effects of
the agents srlggesIs
that they may be beneficial in combination . Clinical trials
that are now being initiated will determine the loner term
utility of this approach .
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